Exelixis, Inc. (EXEL) Analyst Ratings & Price Targets

Exelixis, Inc.

EXEL · NASDAQ-GS

Analyst Consensus

Hold

20 analysts

$65

Current

—

Low

$54

Average

—

High

Average target implies -17.36% versus the current price.

Analyst Ratings Synthesis

The supplied evidence does not provide a single consistent consensus: StockAnalysis.com reports a Buy rating from 19 analysts, while the header labels consensus as unknown and TipRanks references 14 analysts without stating the consensus rating. Targets cluster at $47.33 from Benzinga's latest three analysts and $52.94 from StockAnalysis.com's 19-analyst set, while Simply Wall St.'s analyst fair value is higher at $66, creating a stated spread of $18.67. The most bullish named analyst cannot be identified from the snippets, and neither can the least bullish beyond Truist Securities' Hold. Revisions were mixed-to-positive: fair value rose from $62 to $66 and Truist's target from $51 to $54, but Truist downgraded the stock. The core disagreement is valuation versus earnings and margin improvement.

Rating Actions

No individual rating actions have been captured for EXEL yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BMO CAPITAL MKT

BTIG

CITIGROUP

CITIZENS JMP

GUGGENHEIM SEC.

H C WAINWRIGHT

JEFFERIES & CO.

LEERINK PARTNRS

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RBC CAPITAL

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: EXEL
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: NASDAQ-GS

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on X (Twitter), like Exelixis, Inc.

Key Issues

Bullish view

Net income rose to $0.8 billion from $0.5 billion while revenue increased to $2.3 billion from $2.2 billion, supporting the case that margin improvement can continue to drive earnings.

Bearish view

Revenue growth was modest, and Simply Wall St. says analysts are modeling slightly lower revenue growth, so the recent earnings increase may not be readily repeatable.

Analyst Consensus

See all

Hold

20 analysts

$65

Current

—

Low

$54

Average

—

High

Average target implies -17.36% versus the current price.

Earnings History

BeatMissNo estimate

Exelixis, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers